Cis‐platinum is an ototoxic antineoplastic drug. Evaluation of auditory thresholds in 33 children receiving cis‐platinum shows that a threshold shift at 6 and 8 kHz is first measurable after a cumulative dose of 201 to 300 mg/m 2 . A 35‐ to 40‐dB high‐frequency threshold shift is evident after a cumulative cis‐platinum dose of 301 to 400 mg/m 2 . Increasing cumulative doses of cis‐platinum are associated with a greater degree of hearing loss. Receiver‐operator characteristic curves were used to find a criterion value that effectively identified threshold shifts that were due to cis‐platinum ototoxicity. A 15‐dB or greater shift in the 6‐ and 8‐kHz threshold average identifies a high true‐positive (50%) and low false‐positive (0%) rate of cis‐platinum‐induced hearing loss. Using this criterion, cis‐platinum ototoxicity affected 77% of children who received cis‐platinum (median cumulative dose 360 mg/m 2 ).
No takes yet. Share an insight, caveat, or question.
Pasic et al. (1991) studied this question.